Gennova's MRNA-Based Covid Vaccine Gets Nod For Phase 2/3 Clinical Trials

[email protected]16 Sep, 2021News

India's first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails, the Department of Biotechnology (DBT) said on Tuesday. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine's Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO), it said.